New Edge Advisors, LLC Black Diamond Therapeutics, Inc. Transaction History
New Edge Advisors, LLC
- $15 Billion
- Q3 2024
A detailed history of New Edge Advisors, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 17 shares of BDTX stock, worth $41. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17
Previous 17
-0.0%
Holding current value
$41
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BDTX
# of Institutions
117Shares Held
48.8MCall Options Held
1.84MPut Options Held
1.93M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$26 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$20.6 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$12.2 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$10.8 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.79 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $87.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...